Key information

🔎 Fund Overview

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's product portfolio includes zetomipzomib and KZR-261. The zetomipzomib is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well as to explore preliminary anti-tumor activity. The Company’s drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. Its principal operations are in South San Francisco, California.